Amid stricter regulatory reviews of applications for IPOs across all sectors, such offerings in biotech have been in hiatus on the Chinese mainland in 2024 to date. Meanwhile, three bioventures raised a combined $217.8m as they floated on the Hong Kong Stock Exchange in the first half.

Sun’s deuruxolitinib and Novo Nordisk’s insulin icodec stand out as new molecular entities among the small cluster of US FDA user fee goal dates in July.

Public Company Edition: Alumis grosses $250m after it planned to raise up to $317.7m in its IPO. Also, Zealand adds $1bn in a post-data offering, Tectonic and Eliem close $130.7m and $120m private placements to support recent mergers, and Ginkgo cuts 35% of its workforce.

Lotus will look forward to adding ophthalmic and respiratory products to its growing portfolio after striking a deal to swallow up Teva’s operations in Thailand.